Taken together, detection of KRAS c.35G>A, p.(Gly12Asp) variant using LB that could not be identified with the tissue workflow, molecularly explained the clinically diagnosed overgrowth syndrome in our patient, hereby providing personalized treatment options including MEK inhibitors. This evidence concerns the gene MAP2K7 and overgrowth syndrome.